Arifulla Khan

Summary

Affiliation: Northwest Clinical Research Center
Country: USA

Publications

  1. ncbi request reprint Placebo response and antidepressant clinical trial outcome
    Arif Khan
    Northwest Clinical Research Center, 1900 116th Avenue NE 112, Bellevue, Washington 98004, USA
    J Nerv Ment Dis 191:211-8. 2003
  2. doi request reprint Magnitude of placebo response and response variance in antidepressant clinical trials using structured, taped and appraised rater interviews compared to traditional rating interviews
    Arif Khan
    Northwest Clinical Research Center, 1951 152nd Place NE, Bellevue, WA 98007, USA Department of Psychiatry and Behavioral Science, Duke University School of Medicine, Durham, NC, USA Electronic address
    J Psychiatr Res 51:88-92. 2014
  3. pmc A systematic review of comparative efficacy of treatments and controls for depression
    Arif Khan
    Northwest Clinical Research Center, Bellevue, Washington, United States of America
    PLoS ONE 7:e41778. 2012
  4. ncbi request reprint Placebo response in depression: a perspective for clinical practice
    Arif Khan
    Northwest Clinical Research Center, Bellevue, WA, USA
    Psychopharmacol Bull 41:91-8. 2008
  5. ncbi request reprint Relationship between depression severity entry criteria and antidepressant clinical trial outcomes
    Arif Khan
    Northwest Clinical Research Center, Bellevue, Washington 98004, USA
    Biol Psychiatry 62:65-71. 2007
  6. ncbi request reprint Psychiatric diagnosis and clinical trial completion rates: analysis of the FDA SBA reports
    Arif Khan
    Northwest Clinical Research Center, Bellevue, WA 98004, USA
    Neuropsychopharmacology 32:2422-30. 2007
  7. ncbi request reprint Suicide risk analysis among patients assigned to psychotropics and placebo
    Arif Khan
    Northwest Clinical Research Center, Bellevue, WA 98004, USA
    Psychopharmacol Bull 39:6-14. 2006
  8. ncbi request reprint Double-blind comparison of escitalopram and duloxetine in the acute treatment of major depressive disorder
    Arif Khan
    Northwest Clinical Research Center, Bellevue, WA 98004, USA
    Clin Drug Investig 27:481-92. 2007
  9. ncbi request reprint The persistence of the placebo response in antidepressant clinical trials
    Arif Khan
    Northwest Clinical Research Center, Bellevue, WA 98004, USA
    J Psychiatr Res 42:791-6. 2008
  10. ncbi request reprint Mortality risk in patients with schizophrenia participating in premarketing atypical antipsychotic clinical trials
    Arif Khan
    Northwest Clinical Research Center, Bellevue, Wash, USA
    J Clin Psychiatry 68:1828-33. 2007

Detail Information

Publications40

  1. ncbi request reprint Placebo response and antidepressant clinical trial outcome
    Arif Khan
    Northwest Clinical Research Center, 1900 116th Avenue NE 112, Bellevue, Washington 98004, USA
    J Nerv Ment Dis 191:211-8. 2003
    ....
  2. doi request reprint Magnitude of placebo response and response variance in antidepressant clinical trials using structured, taped and appraised rater interviews compared to traditional rating interviews
    Arif Khan
    Northwest Clinical Research Center, 1951 152nd Place NE, Bellevue, WA 98007, USA Department of Psychiatry and Behavioral Science, Duke University School of Medicine, Durham, NC, USA Electronic address
    J Psychiatr Res 51:88-92. 2014
    ....
  3. pmc A systematic review of comparative efficacy of treatments and controls for depression
    Arif Khan
    Northwest Clinical Research Center, Bellevue, Washington, United States of America
    PLoS ONE 7:e41778. 2012
    ..We hypothesized that the differences between approved depression treatments and controls would be small...
  4. ncbi request reprint Placebo response in depression: a perspective for clinical practice
    Arif Khan
    Northwest Clinical Research Center, Bellevue, WA, USA
    Psychopharmacol Bull 41:91-8. 2008
    ..For the practicing clinician, the best available data suggest that clinically depressed patients warrant treatment and the most robust available body of data (published and unpublished) would favor the use of antidepressants...
  5. ncbi request reprint Relationship between depression severity entry criteria and antidepressant clinical trial outcomes
    Arif Khan
    Northwest Clinical Research Center, Bellevue, Washington 98004, USA
    Biol Psychiatry 62:65-71. 2007
    ..We assessed whether increasing the minimum prerandomization Hamilton Depression Rating Scale (HAM-D) score to enrich the severity of the depressed sample affects antidepressant trial outcome...
  6. ncbi request reprint Psychiatric diagnosis and clinical trial completion rates: analysis of the FDA SBA reports
    Arif Khan
    Northwest Clinical Research Center, Bellevue, WA 98004, USA
    Neuropsychopharmacology 32:2422-30. 2007
    ..These findings may help in the design of future psychopharmacology clinical trials...
  7. ncbi request reprint Suicide risk analysis among patients assigned to psychotropics and placebo
    Arif Khan
    Northwest Clinical Research Center, Bellevue, WA 98004, USA
    Psychopharmacol Bull 39:6-14. 2006
    ..These findings suggest that the high suicide risk among clinical trial participants is not significantly affected by psychotropics...
  8. ncbi request reprint Double-blind comparison of escitalopram and duloxetine in the acute treatment of major depressive disorder
    Arif Khan
    Northwest Clinical Research Center, Bellevue, WA 98004, USA
    Clin Drug Investig 27:481-92. 2007
    ..This study evaluated the efficacy and safety of escitalopram versus duloxetine in the acute treatment of patients with moderate to severe major depressive disorder...
  9. ncbi request reprint The persistence of the placebo response in antidepressant clinical trials
    Arif Khan
    Northwest Clinical Research Center, Bellevue, WA 98004, USA
    J Psychiatr Res 42:791-6. 2008
    ..The widely held belief that the placebo response in depression is short-lived appears to be based largely on intuition and perhaps wishful thinking...
  10. ncbi request reprint Mortality risk in patients with schizophrenia participating in premarketing atypical antipsychotic clinical trials
    Arif Khan
    Northwest Clinical Research Center, Bellevue, Wash, USA
    J Clin Psychiatry 68:1828-33. 2007
    ....
  11. ncbi request reprint Suicide risk and symptom reduction in patients assigned to placebo in duloxetine and escitalopram clinical trials: analysis of the FDA summary basis of approval reports
    Arif Khan
    Northwest Clinical Research Center, Bellevue, WA, USA
    Ann Clin Psychiatry 19:31-6. 2007
    ..We assessed suicide and suicide attempt risk as well as symptom reduction among 3,282 depressed patients participating in duloxetine and escitalopram clinical trials assigned to either an antidepressant or placebo...
  12. doi request reprint Current evidence for aripiprazole as augmentation therapy in major depressive disorder
    Arif Khan
    Department of Psychiatry and Behavioral Sciences, Duke University, Durham, NC, USA
    Expert Rev Neurother 8:1435-47. 2008
    ..At doses of 2-15 mg/day aripiprazole was efficacious and well tolerated as adjunctive therapy to antidepressants in patients who had not responded to monotherapy...
  13. doi request reprint Vilazodone, a novel dual-acting serotonergic antidepressant for managing major depression
    Arif Khan
    Northwest Clinical Research Center, Bellevue, WA 98004, USA
    Expert Opin Investig Drugs 18:1753-64. 2009
    ..Vilazodone offers a dual mechanism of action, good general tolerability with the potential for less impairment of sexual function than selective serotonin reuptake inhibitors and the possibility of personalized treatment for MDD...
  14. doi request reprint Why has the antidepressant-placebo difference in antidepressant clinical trials diminished over the past three decades?
    Arif Khan
    Northwest Clinical Research Center, Bellevue, WA 98007, USA
    CNS Neurosci Ther 16:217-26. 2010
    ..Further, these data suggest that the results of more recent placebo controlled trials do not adequately inform clinicians about the potential utility of antidepressants...
  15. doi request reprint Are the colors and shapes of current psychotropics designed to maximize the placebo response?
    Arif Khan
    Northwest Clinical Research Center, 1951 152nd Pl NE 200, Bellevue, WA 98007, USA
    Psychopharmacology (Berl) 211:113-22. 2010
    ..Patient expectations are an important aspect of the placebo response. Color and shape of a medication lead to perceptions that an agent is stimulating or calming, strong or weak...
  16. doi request reprint Antidepressant-placebo differences in 16 clinical trials over 10 years at a single site: role of baseline severity
    Arif Khan
    Northwest Clinical Research Center, 1951 152nd Place NE Suite 200, Bellevue, WA 98007, USA
    Psychopharmacology (Berl) 214:961-5. 2011
    ..The current study was designed to examine antidepressant-placebo difference scores and baseline severity of depression over a 10-year period in a sample of depressed patients enrolled at a single clinical trial site...
  17. doi request reprint A randomized, double-blind, placebo-controlled, 8-week study of vilazodone, a serotonergic agent for the treatment of major depressive disorder
    Arif Khan
    Northwest Clinical Research Center, 1951 152nd Pl NE, Ste 200, Bellevue, WA 98007, USA
    J Clin Psychiatry 72:441-7. 2011
    ..To evaluate the efficacy, and further establish the safety profile, of oral once-daily vilazodone, a potent and selective serotonin 1A receptor partial agonist and reuptake inhibitor, in the treatment of major depressive disorder (MDD)...
  18. doi request reprint A randomized, double-blind study of once-daily extended release quetiapine fumarate (quetiapine XR) monotherapy in patients with generalized anxiety disorder
    Arifulla Khan
    Northwest Clinical Research Center, Bellevue, WA 98007, USA
    J Clin Psychopharmacol 31:418-28. 2011
    ..Quetiapine XR (50/150 mg/d) monotherapy was effective at week 8 in patients with GAD; symptom improvement was seen at week 1 for all doses (50/150/300 mg/d). Safety and tolerability were consistent with the known profile of quetiapine...
  19. doi request reprint Differential pattern of response in mood symptoms and suicide risk measures in severely ill depressed patients assigned to citalopram with placebo or citalopram combined with lithium: role of lithium levels
    Arif Khan
    Northwest Clinical Research Center, Bellevue, WA 98007, USA
    J Psychiatr Res 45:1489-96. 2011
    ..Further, lithium when used in therapeutic doses may augment such effects. These data warrant further exploration of lithium and an antidepressant combination for anti-suicidal effects...
  20. ncbi request reprint BMI, sex, and antidepressant response
    Arif Khan
    Northwest Clinical Research Center, Bellevue, WA, USA
    J Affect Disord 99:101-6. 2007
    ..However, to date no studies have measured the impact of body mass index (BMI) on men's and women's response to selective serotonin re-uptake inhibitors or placebo...
  21. ncbi request reprint Severity of depression and response to antidepressants and placebo: an analysis of the Food and Drug Administration database
    Arif Khan
    Northwest Clinical Research Center, Bellevue, Washington, USA
    J Clin Psychopharmacol 22:40-5. 2002
    ..Early discontinuation was more frequent among patients whose mean initial HAM-D scores were higher. These data may help inform the design of future antidepressant clinical trials...
  22. ncbi request reprint Medical aspects of capital punishment executions
    Arif Khan
    Northwest Clinical Research Center, Bellevue, WA, USA
    J Forensic Sci 47:847-51. 2002
    ..These data suggest that human executions are difficult to carry out. Human executions are associated with significant physical complications. These data may help inform future discussions on human executions...
  23. ncbi request reprint Are placebo controls necessary to test new antidepressants and anxiolytics?
    Arif Khan
    Northwest Clinical Research Center, Bellevue, WA 98004, USA
    Int J Neuropsychopharmacol 5:193-7. 2002
    ....
  24. ncbi request reprint Relative sensitivity of the Montgomery-Asberg Depression Rating Scale, the Hamilton Depression rating scale and the Clinical Global Impressions rating scale in antidepressant clinical trials
    A Khan
    Northwest Clinical Research Center, Bellevue, WA 98004, USA
    Int Clin Psychopharmacol 17:281-5. 2002
    ..These data suggest that MADRS is as sensitive an instrument as HAM-D for detecting antidepressant efficacy in clinical trials. Thus, MADRS may be a desirable tool in large-scale, pivotal antidepressant clinical trials...
  25. ncbi request reprint Frequency of positive studies among fixed and flexible dose antidepressant clinical trials: an analysis of the food and drug administration summary basis of approval reports
    Arif Khan
    Northwest Clinical Research Center, Bellevue, WA, USA
    Neuropsychopharmacology 28:552-7. 2003
    ..05) compared to fixed dose trials. Symptom reduction was similar with antidepressants in the flexible and fixed dose trials. Further, the primary function of finding a dose-response relationship was not found among the fixed dose studies...
  26. ncbi request reprint Suicide rates in clinical trials of SSRIs, other antidepressants, and placebo: analysis of FDA reports
    Arif Khan
    Northwest Clinical Research Center, Bellevue, Washington, USA
    Am J Psychiatry 160:790-2. 2003
    ..The authors analyzed reports from randomized controlled trials to compare suicide rates among depressed patients assigned to an SSRI, other antidepressants, or placebo...
  27. ncbi request reprint Relative sensitivity of the Montgomery-Asberg depression rating scale, the Hamilton depression rating scale and the Clinical Global Impressions rating scale in antidepressant clinical trials: a replication analysis
    Arif Khan
    North west Clinical Research Center, Bellevue, Washington, USA
    Int Clin Psychopharmacol 19:157-60. 2004
    ..01). Further research is needed to examine which scale is the most appropriate to use for each particular antidepressant clinical trial...
  28. ncbi request reprint Research design features and patient characteristics associated with the outcome of antidepressant clinical trials
    Arif Khan
    Northwest Clinical Research Center, Number 112, 1900 116th Avenue NE, Bellevue, WA 98004, USA
    Am J Psychiatry 161:2045-9. 2004
    ..The authors examined which, if any, research design features and patient characteristics would significantly differ between successful and unsuccessful antidepressant trials...
  29. ncbi request reprint Effect of lamotrigine on cognitive complaints in patients with bipolar I disorder
    Arifulla Khan
    Northwest Clinical Research Center, Bellevue, Wash 98004, USA
    J Clin Psychiatry 65:1483-90. 2004
    ..This analysis describes the effects of bipolar I disorder on self-reported neurocognitive measures and remediation of these deficits with lamotrigine therapy...
  30. ncbi request reprint Sex differences in antidepressant response in recent antidepressant clinical trials
    Arif Khan
    Northwest Clinical Research Center, 1900 116th Avenue NE 112, Bellevue, WA 98004, USA
    J Clin Psychopharmacol 25:318-24. 2005
    ..These findings also raise the possibility that antidepressants may work somewhat differently in men and women...
  31. ncbi request reprint Magnitude of placebo response and drug-placebo differences across psychiatric disorders
    Arif Khan
    Northwest Clinical Research Center, Bellevue, WA, USA
    Psychol Med 35:743-9. 2005
    ..Placebo response, drug response, and drug-placebo differences appear to vary among psychiatric conditions...
  32. ncbi request reprint Severity of depressive symptoms and response to antidepressants and placebo in antidepressant trials
    Arif Khan
    Northwest Clinical Research Center, Bellevue, MA, USA
    J Psychiatr Res 39:145-50. 2005
    ..These findings may help in the design of future antidepressant clinical trials...
  33. ncbi request reprint Extended release quetiapine fumarate monotherapy for major depressive disorder: results of a double-blind, randomized, placebo-controlled study
    Richard Weisler
    Department of Psychiatry, University of North Carolina, Chapel Hill, Chapel Hill, NC, USA
    CNS Spectr 14:299-313. 2009
    ..Once-daily extended release quetiapine fumarate (quetiapine XR) monotherapy was evaluated in major depressive disorder (MDD)...
  34. ncbi request reprint Suicide risk in patients with anxiety disorders: a meta-analysis of the FDA database
    Arif Khan
    Northwest Clinical Research Center, 1900 116th Avenue NE 112, Bellevue, WA 98004, USA
    J Affect Disord 68:183-90. 2002
    ..Previous reports of suicide risk in patients with anxiety disorders have been inconsistent...
  35. ncbi request reprint Study designs and outcomes in antidepressant clinical trials
    Arif Khan
    Northwest Clinical Research Center, Bellevue, WA, USA
    Essent Psychopharmacol 6:221-6. 2005
    ..Flexible dosing paradoxically reduces the response to placebo without augmenting the response to the antidepressant. All of these findings suggest that the use of placebo is mandatory when assessing new antidepressants...
  36. ncbi request reprint An application of the revised CONSORT standards to FDA summary reports of recently approved antidepressants and antipsychotics
    Arif Khan
    Northwest Clinical Research Center, Bellevue, Washington 98004, USA
    Biol Psychiatry 52:62-7. 2002
    ..They are rarely accessed but may have public health utility. Thus, we assessed these reports to evaluate if the clinical data can be used for comparing psychotropics...
  37. ncbi request reprint Multiple-dose pharmacokinetics of fluvoxamine in children and adolescents
    Michael Labellarte
    Johns Hopkins Medical Institutions, Baltimore, USA
    J Am Acad Child Adolesc Psychiatry 43:1497-505. 2004
    ..To determine the pharmacokinetics of fluvoxamine in children and adolescents and to compare pharmacokinetic data from adolescents to adults from a previous study...
  38. ncbi request reprint A double-blind, placebo-controlled study of a flexible dose of venlafaxine ER in adult outpatients with generalized social anxiety disorder
    Karl Rickels
    Department of Psychiatry, University of Pennsylvania Medical Center, Philadelphia, PA 19104 3309, USA
    J Clin Psychopharmacol 24:488-96. 2004
    ..Venlafaxine ER was safe, well tolerated, and efficacious in the short-term treatment of generalized social anxiety disorder...
  39. ncbi request reprint Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study)
    Michael E Thase
    Western Psychiatric Institute and Clinic, University of Pittsburgh Medical Center, Pittsburgh, PA 15213 2593, USA
    J Clin Psychopharmacol 26:600-9. 2006
    ..This study demonstrates that quetiapine monotherapy is an effective and well-tolerated treatment for depressive episodes in bipolar disorder, confirming the results observed from a previous study (BipOLar DEpRession [BOLDER] I)...
  40. ncbi request reprint Treatment with venlafaxine extended release after SSRI nonresponse or intolerance: a randomized comparison of standard- and higher-dosing strategies
    Michael E Thase
    University of Pittsburgh Medical Center, Department of Psychiatry, Pittsburgh, PA 15213 2593, USA
    J Clin Psychopharmacol 26:250-8. 2006
    ....